Meta‐analysis examining the epidemiology of clozapine‐associated neutropenia

  title={Meta‐analysis examining the epidemiology of clozapine‐associated neutropenia},
  author={Nicholas Myles and Hannah Myles and Shelley Xia and Matthew Large and Stephen R. Kisely and Cherrie A Galletly and Robert J Bird and Dan J. Siskind},
  journal={Acta Psychiatrica Scandinavica},
Clozapine is associated with life‐threatening neutropenia. There are no previous meta‐analyses of the epidemiology of clozapine‐associated neutropenia. 

Risk factors for clozapine‐induced myocarditis and cardiomyopathy: A systematic review and meta‐analysis

A systematic review and meta‐analysis to identify potential risk factors for clozapine‐induced myocarditis and cardiomyopathy and to aid treatment decision‐making for clinicians, patients and their carers.

Late-onset clozapine-induced neutropenia treated with lithium

  • P. T. Durmus
  • Psychology, Medicine
    Dusunen Adam: The Journal of Psychiatry and Neurological Sciences
  • 2019
A case of clozapine-induced neutropenia in a schizophrenic patient seen after 7 years of clazapine use and its treatment with lithium supplementation is presented.

Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective

An overview of the current understanding of the genetics of clozapine-associated agranulocytosis and neutropenia is provided and recent findings relating to the Duffy-null genotype and its association with benign neutropania in individuals with African ancestry are described.

Clozapine and chemotherapy: a dangerous couple or a necessary partnership?

A 48-year-old man with a history of schizophrenia was diagnosed with B-cell lymphoma of the small bowel after neutropaenia occurred secondary to chemotherapy, which led to clozapine being discontinued, leading to improved mental state and the treatment of lymphoma.

Clozapine and chemotherapy: a dangerous couple or a necessary partnership?

A 48year-old man with a history of schizophrenia was diagnosed with Bcell lymphoma of the small bowel, which led to clozapine being discontinued, which resulted in the deterioration of his mental state, affecting the treatment of lymphoma.

Recognition and management of clozapine adverse effects: A systematic review and qualitative synthesis

Clozapine is substantially underutilized in most countries and clinician factors including lack of knowledge and concerns about adverse drug effects (ADEs) contribute strongly to treatment

The effect of COVID-19 on absolute neutrophil counts in patients taking clozapine

Patients taking clozapine who develop neutroapaenia during COVID-19 infection should be investigated and monitored as in normal practice, because changes in neutrophil counts cannot be assumed to be due to the viral infection.

Rechallenge Following Clozapine-Associated Eosinophilia: A Case Report and Literature Review.

The case of a 50-year-old woman with a history of TRS and prior clozapine discontinuation secondary to eosinophilia is presented.

Clozapine-associated neutropenia in Latin America: incidence report of 5380 Chilean users.

The evidence of a very low risk for severe neutropenia and the behaviour of mild neutropania cases confirm the feasibility of changes in Latin American clozapine guidelines using current Food and Drug Administration's recommendations as a model.



Neutropenia and Agranulocytosis in Patients Receiving Clozapine in the UK and Ireland

The use of a patient monitoring service kept the haematological risks associated with using clozapine within acceptable limits, particularly in view of the benefits of this medication in treatment-resistant schizophrenia.

Active monitoring of 12760 clozapine recipients in the UK and Ireland

The case register yielded valuable information for guiding research into the causes of the haematological reactions in subjects receiving clozapine, and the risk for agranulocytosis in Asian subjects was 2.4 times that in Caucasians.

International trends in clozapine use: a study in 17 countries

This study aimed to assess clozapine use trends on an international scale, using standardised criteria for data analysis.

Agranulocytosis during treatment with clozapine

Within six months of the introduction of the new antipsychotic drug clozapine in Finland, 17 cases of neutropenia or agranulocytosis were recorded amongst about 3000 patients treated, with a high incidence of complications.

Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.

The estimated impact of the CNR on clozapine-related morbidity and mortality over the first 5 years of commercial experience in the United States is reviewed.

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.

The increasing risk of agranulocytosis with age and the reduced incidence after the first six months of treatment provide additional guidelines for the prescription and monitoring of clozapine treatment in the future.

Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis

Clozapine is superior for treatment-refractory disorder but if there is no response by 6 months medications with lower adverse reactions should be considered.

Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia.

Rates of all-cause mortality and self-harm in association with clozapine treatment in individuals with treatment-resistant schizophrenia demonstrate a nearly twofold higher mortality rate and suggest a harmful effect of other antipsychotics regarding self- Harm compared with clazapine.

Idiosyncratic drug-induced agranulocytosis or acute neutropenia

Idiosyncratic drug-induced agranulocytosis or acute neutropenia is an adverse event resulting in a neutrophil count under 0.5 × 109/l and healthcare professionals should be aware of this adverse event and its management.

Population-based drug-induced agranulocytosis.

Agranulocytosis is rare but serious, and a few drugs account for two thirds of the cases, and the results provide reassurance regarding the risk associated with a number of newly marketed drugs.